FDA warning letter: Thrive Health Solutions
What the FDA told Thrive Health Solutions in February 2026 about tirzepatide — and the closeout letter that followed.
“Unapproved New Drug Products You do not have any FDA-approved applications on file for the drug products that you repackage, such as NAD+ 50 mg/mL and MEGALean (Tirzepatide/Cyanocobalamin) Injections 10mg/20mg/mL. 2 These products are unapproved new drugs under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)].”
What an FDA warning letter is
It is a letter. The FDA writes to a company to say which of its practices the agency believes break the law, and asks it to fix them. That is the whole mechanism: a written notice, published so anyone can read it.
It is the FDA’s position, not a court’s finding. The company can reply, and can disagree. The agency states in these letters that failing to address the problems may lead to further action such as seizure or an injunction — which tells you the letter itself is not yet either of those things.
A warning letter does not recall a product, suspend a licence or close a business. It does not mean that medicine already dispensed was unsafe. When the FDA is satisfied the problems are fixed, it publishes a closeout letter, as it has for this one.
What it does tell you is that a regulator looked at this company and wanted something changed. The useful question is what — and the quoted passage above answers it more precisely than any summary can.
What the letter says
| Field | What the letter states | Source |
|---|---|---|
| Recipient | Thrive Health and Wellness, LLC dba Thrive Health Solutions | FDA warning letter |
| Issued | Feb 9, 2026 | FDA warning letter |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA warning letter |
| FDA reference | MARCS-CMS 714891 | FDA warning letter |
| Location | Englewood, CO, United States | FDA warning letter |
| Subject | Compounding Pharmacy/Adulterated Drug Products | FDA warning letter |
| What it concerns | How the medicine was made | Read from the subject line |
| Medication named | Tirzepatide | Letter text |
| Status | Closed out by the FDA. Read the closeout letter | FDA warning letter list |
- FDA warning lettersPublished compliance actions, updated weekly
- FDA registered outsourcing facilities503B register, with inspection and enforcement status
- FDA National Drug Code directoryLabeler, product and package listings
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.